Evaluating vaccination strategies for reducing infant respiratory syncytial virus infection in low-income settings

BMC Medicine
|April 11, 2015
PubMed

Insights

School-aged children are key in transmitting respiratory syncytial virus (RSV) to infants. Vaccinating students annually offers a viable strategy to significantly reduce infant RSV infections, complementing infant immunization efforts.

Area of Science:

  • Virology
  • Epidemiology
  • Public Health

Background:

  • Respiratory syncytial virus (RSV) is a major cause of severe respiratory illness and hospitalization in young children globally.
  • Infant RSV infections are particularly severe due to immunological immaturity, making infants a challenging vaccine target.
  • Current vaccine development is ongoing, but no immunization programs are established for RSV prevention.

Purpose of the Study:

  • To investigate RSV transmission dynamics in a rural Kenyan population using an individual-based model.
  • To evaluate the effectiveness of alternative vaccination strategies for reducing infant RSV infections.
  • To identify optimal target groups for potential RSV vaccination programs.

Main Methods:

  • Development of an individual-based model incorporating socio-demographic population structure.
  • Simulation of RSV transmission patterns in a rural Kenyan setting.
  • Assessment of vaccination strategies targeting different age groups and pregnant women.

Main Results:

  • Household transmission accounts for 39% of infant RSV infections, with school-aged children being the primary source (55%).
  • Annual vaccination of students is projected to reduce infant RSV infections by 35.6% over 10 years, comparable to infant immunization (41.5%).
  • Vaccinating pregnant women to boost maternal antibody protection could decrease infant RSV infections by 31.5%.

Conclusions:

  • Vaccination strategies targeting school-aged children show promise for reducing infant RSV burden.
  • Maternal immunization during pregnancy may offer a complementary approach to protect infants.
  • Future RSV vaccine development should consider diverse target populations beyond infants to maximize public health impact.
Abstract